InnoPharma, Inc.

ACTIVE

新泽西州米德尔塞克斯县, New Jersey, United Statesinnopharmainc.comSubsidiary51–100 employeesEstablished: 2005-01-01

Part of PFIZER INC.

Clinical Trials

4 active

Approvals

Total approvals

Agencies

Regulatory bodies

Founded

2005

Overview

Trial Phase Distribution

Phase

Trials

Not Applicable

33.3%

Phase 3

22.2%

Phase 1

11.1%

Trial Status Distribution

Not yet recruiting

44.4%

Recruiting

33.3%

Unknown

22.2%

Clinical Trials

Trials sponsored by this organization (9)

A Single-Dose, Randomized, Open-Label, Crossover, Pilot, Comparative Bioavailability Study of Aprepitant 130 mg Injection Versus EMEND Registered Trademark 150 mg Injection and EMEND Registered Trademark 125 mg Capsules in Healthy Male and Female Volunteers under Fasting Conditions.

Phase 1

Recruiting

interventional

May 201418 participants

STUDY TO DETERMINE THE THERAPEUTIC EQUIVALENCE OF GENERIC BRINZOLAMIDE 1% OPHTHALMIC SUSPENSION MANUFACTURED BY INNOPHARMA INC

Phase 3

Unknown

interventional

Jul 2012286 participants

STUDY TO DETERMINE THE THERAPEUTIC EQUIVALENCE OF GENERIC BRINZOLAMIDE 1% OPHTHALMIC SUSPENSION MANUFACTURED BY INNOPHARMA INC

Phase 3

Unknown

286 participants

Bioequivalence study of Nisoldipine 34mg ER oral tablet

Not Applicable

Not yet recruiting

48 participants

Bioequivalence study of Nisoldipine 8.5mg ER oral tablet

Not Applicable

Recruiting

48 participants

Page 1 of 2

Approvals

No approval data available

News

No news articles found

Back to Organizations

InnoPharma, Inc.

Overview

Trial Phase Distribution

Trial Status Distribution

Clinical Trials

Trials sponsored by this organization (9)

A Single-Dose, Randomized, Open-Label, Crossover, Pilot, Comparative Bioavailability Study of Aprepitant 130 mg Injection Versus EMEND Registered Trademark 150 mg Injection and EMEND Registered Trademark 125 mg Capsules in Healthy Male and Female Volunteers under Fasting Conditions.

Bioequivalence study of Nisoldipine 17 mg ER oral tablet

Bioequivalence study of Nisoldipine 34mg ER oral tablet

Bioequivalence study of Nisoldipine 8.5mg ER oral tablet

STUDY TO DETERMINE THE THERAPEUTIC EQUIVALENCE OF GENERIC BRINZOLAMIDE 1% OPHTHALMIC SUSPENSION MANUFACTURED BY INNOPHARMA INC

STUDY TO DETERMINE THE THERAPEUTIC EQUIVALENCE OF GENERIC BRINZOLAMIDE 1% OPHTHALMIC SUSPENSION MANUFACTURED BY INNOPHARMA INC

Bioequivalence study of Nisoldipine 34mg ER oral tablet

Bioequivalence study of Nisoldipine 8.5mg ER oral tablet

Approvals

News